Burning Rock Biotech Limited (BNR)

Burning Rock Biotech Limited specializes in developing and providing cancer therapy selection tests in China. The company leverages next-generation sequencing technology to offer a range of diagnostic and prognostic tests for various cancer types.

49/100 AI Score MCap 26M Vol 57K

Company Overview

CEOYusheng Han
Employees674
HeadquartersGuangzhou, CN
IPO Year2020

Burning Rock Biotech: Pioneering precision oncology in China with advanced NGS-based cancer therapy selection, prognosis, and R&D services, offering investors a unique opportunity to capitalize on the rapidly growing Chinese cancer diagnostics market and strategic collaborations.

Investment Thesis

Investing in Burning Rock Biotech presents a compelling opportunity to capitalize on the rapidly expanding cancer diagnostics market in China. With a gross margin of 73.0%, the company demonstrates a strong ability to generate revenue from its core testing services. While currently operating at a loss with a P/E of -2.09 and a profit margin of -22.5%, strategic collaborations and in-licensing agreements, such as those with Myriad Genetics and Oncocyte Corporation, are expected to drive future revenue growth and improve profitability. Key value drivers include the increasing adoption of NGS-based cancer therapy selection, the expansion of the company's product portfolio, and continued partnerships with pharmaceutical companies. Upcoming catalysts include regulatory approvals for new tests and expansion of in-hospital business.

Key Highlights

  • Market capitalization of $0.04 billion reflects the company's current valuation, presenting a potential entry point for investors.
  • Gross margin of 73.0% indicates strong pricing power and efficient cost management in its core testing services.
  • Negative P/E ratio of -2.09 suggests the company is currently unprofitable, highlighting the need for improved operational efficiency and revenue growth.
  • Beta of 1.32 indicates higher volatility compared to the market, suggesting potential for higher returns but also increased risk.
  • Strategic collaborations with AstraZeneca, Bayer, Johnson & Johnson, and Merck KGaA validate the company's technology and market position.

Competitors

Strengths

  • Proprietary NGS-based testing technology.
  • Strong relationships with leading hospitals and pharmaceutical companies in China.
  • Extensive database of genomic information specific to the Chinese population.
  • Diverse product portfolio covering various cancer types.

Weaknesses

  • Currently unprofitable with a negative P/E ratio.
  • High beta indicating higher volatility.
  • Reliance on regulatory approvals for new tests.
  • Limited geographic diversification outside of China.

Catalysts

  • Upcoming: Regulatory approvals for new cancer diagnostic tests.
  • Ongoing: Expansion of the In-Hospital Business segment.
  • Ongoing: Increased adoption of liquid biopsy tests.
  • Ongoing: Strategic partnerships with pharmaceutical companies for companion diagnostics development.

Risks

  • Potential: Intense competition from other diagnostic companies.
  • Potential: Changes in regulatory landscape and reimbursement policies in China.
  • Potential: Technological obsolescence of NGS-based testing platforms.
  • Ongoing: Reliance on a single geographic market (China).
  • Ongoing: Current unprofitability and need for improved operational efficiency.

Growth Opportunities

  • Expansion of In-Hospital Business: Burning Rock has a significant opportunity to expand its In-Hospital Business segment. By establishing partnerships with more hospitals and increasing the adoption of its testing services within these facilities, the company can directly reach a larger patient population and capture a greater share of the market. The Chinese hospital market is vast, and increasing awareness of precision medicine will drive adoption. This expansion could contribute significantly to revenue growth within the next 2-3 years.
  • Increased Adoption of Liquid Biopsy Tests: Liquid biopsy is a rapidly growing area in cancer diagnostics, offering a less invasive alternative to traditional tissue biopsies. Burning Rock's OncoCompass IO and OncoCompass Target tests position the company well to capitalize on this trend. As liquid biopsy technology becomes more refined and widely accepted, the demand for these tests is expected to increase significantly, providing a substantial growth opportunity for Burning Rock. Market size is projected to reach multi-billions in the next 5 years.
  • Development of New Cancer Diagnostic Tests: Burning Rock can continue to invest in research and development to expand its portfolio of cancer diagnostic tests. By developing new tests for additional cancer types or improving the accuracy and sensitivity of existing tests, the company can attract new customers and increase its market share. Focus on early cancer detection can be a key differentiator. Timeline for new test development is typically 2-3 years.
  • Strategic Partnerships with Pharmaceutical Companies: Burning Rock's existing collaborations with pharmaceutical companies like AstraZeneca and Bayer provide a strong foundation for future partnerships. By expanding these collaborations to include more companies and focusing on joint development of companion diagnostics for new cancer therapies, Burning Rock can generate additional revenue and strengthen its position as a key player in the cancer diagnostics market. These partnerships also provide access to valuable clinical data and expertise.
  • Geographic Expansion within China: While Burning Rock is headquartered in Guangzhou, it has the opportunity to expand its geographic reach within China. By establishing regional offices and partnerships with hospitals and clinics in other major cities, the company can tap into new markets and increase its overall revenue. China's vast geography and diverse population present significant opportunities for growth. This expansion can be phased over the next 3-5 years.

Opportunities

  • Expansion of In-Hospital Business segment.
  • Increased adoption of liquid biopsy tests.
  • Development of new cancer diagnostic tests.
  • Further strategic partnerships with pharmaceutical companies.

Threats

  • Intense competition in the cancer diagnostics market.
  • Changes in regulatory landscape and reimbursement policies.
  • Potential for technological obsolescence.
  • Economic slowdown in China.

Competitive Advantages

  • Proprietary NGS-based testing technology.
  • Strong relationships with leading hospitals and pharmaceutical companies in China.
  • Extensive database of genomic information specific to the Chinese population.
  • Strategic partnerships with international diagnostic companies like Myriad Genetics and Oncocyte Corporation.

About

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech Limited is at the forefront of cancer precision medicine in the People's Republic of China. The company operates through three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. Burning Rock's core expertise lies in developing and commercializing next-generation sequencing (NGS)-based cancer therapy selection and prognosis prediction tests. These tests are applicable to a wide array of cancer types, including lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company utilizes both tissue and liquid biopsy samples to provide comprehensive genomic profiling. Key products include OncoCompass IO and OncoScreen IO for immune-oncology applications, OncoCompass Target for NSCLC, ColonCore for gastrointestinal cancers, and OncoScreen ParpMatch/OncoCompass ParpMatch for homologous recombination deficiency assessment. Burning Rock has also established strategic partnerships to expand its offerings, including agreements with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing and Oncocyte Corporation to in-license DetermaRx for early-stage lung cancer. Further bolstering its position, Burning Rock collaborates with pharmaceutical giants such as AstraZeneca, Bayer, Johnson & Johnson, and Merck KGaA on clinical trials and research studies.

What They Do

  • Develop and provide cancer therapy selection tests.
  • Offer next-generation sequencing (NGS)-based tests.
  • Provide tests for various cancer types, including lung, gastrointestinal, and breast cancer.
  • Utilize both tissue and liquid biopsy samples.
  • Offer prognosis prediction tests.
  • Provide services through Central Laboratory, In-Hospital, and Pharma R&D segments.
  • Collaborate with pharmaceutical companies on clinical trials.

Business Model

  • Central Laboratory Business: Processing and analyzing patient samples in its own laboratory.
  • In-Hospital Business: Providing testing services directly within hospitals.
  • Pharma Research and Development Services: Partnering with pharmaceutical companies to develop and commercialize companion diagnostics.
  • Licensing Agreements: In-licensing and commercializing diagnostic tests from other companies.

Industry Context

Burning Rock Biotech operates within the rapidly evolving medical diagnostics and research industry, specifically focusing on cancer therapy selection in China. The market is driven by increasing cancer incidence, growing demand for personalized medicine, and advancements in NGS technologies. The competitive landscape includes companies like ADVB, AEMD, ALUR, AMS, and AYTU, each vying for market share in various segments of the diagnostics space. Burning Rock differentiates itself through its focus on NGS-based tests tailored to the Chinese population and its strategic partnerships with leading pharmaceutical companies. The global NGS market is projected to reach billions of dollars in the coming years, offering significant growth potential for companies like Burning Rock.

Key Customers

  • Hospitals and clinics.
  • Oncologists and other healthcare professionals.
  • Pharmaceutical companies.
  • Patients seeking personalized cancer treatment.
AI Confidence: 72% Updated: 2/8/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $132M -$17M $-15.56
Q2 2025 $149M -$10M $-9.01
Q1 2025 $133M -$14M $-12.54
Q4 2024 $126M -$81M $-78.65

Source: Company filings

Chart & Info

Price Chart

Burning Rock Biotech Limited (BNR) stock price: $24.48 (+4.80, +24.39%)

Why Bull

  • •Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
  • •The community sentiment has shifted positively with discussions highlighting innovative developments in their biotechnology solutions.
  • •Market perception has been buoyed by recent partnerships that enhance their research capabilities and expand their market reach.
  • •Increased attention on cancer diagnostics aligns with Burning Rock's focus, positioning them favorably in a growing sector.

Why Bear

  • •Concerns about regulatory hurdles have been raised, which could impact the timeline for product approvals and market entry.
  • •Recent community discussions have highlighted skepticism regarding the scalability of their technology, raising doubts about long-term growth.
  • •The competitive landscape in biotech is fierce, with many emerging players that could overshadow Burning Rock's advancements.
  • •Market sentiment has shown signs of caution, reflecting broader economic uncertainties that may affect investment in biotech firms.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
56,466

Rationale

AI-generated technical analysis for BNR including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Burning Rock Biotech Limited (BNR) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for BNR.

Make a Prediction

Set your price target for Burning Rock Biotech Limited (BNR), choose a timeframe, and track your prediction accuracy.

Current price: $24.48

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BNR.

Price Targets

Wall Street price target analysis for BNR.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

48.5/100

Score Factors

  • Revenue Growth 4/100

    Revenue grew only 10.9% YoY, suggesting the company is in a slower growth phase.

  • Gross Margin 10/100

    Gross margin of 73.0% shows excellent pricing power and a strong competitive moat.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates BNR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Burning Rock Biotech Limited do?

Burning Rock Biotech Limited is a Chinese company specializing in cancer therapy selection and prognosis prediction through next-generation sequencing (NGS) technology. They offer a range of diagnostic tests for various cancer types using both tissue and liquid biopsy samples. The company operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services, providing comprehensive genomic profiling to guide personalized cancer treatment decisions and collaborating with pharmaceutical companies on companion diagnostics.

Is BNR stock a good buy?

BNR stock presents a speculative investment opportunity. While the company boasts a high gross margin of 73.0%, it is currently unprofitable with a negative P/E ratio. Growth catalysts include expansion of the In-Hospital Business and increased adoption of liquid biopsy tests. Investors should carefully consider the company's high beta, reliance on the Chinese market, and the competitive landscape before investing. Successful execution of growth strategies and improved profitability are crucial for long-term value creation.

What are the main risks for BNR?

Burning Rock Biotech faces several key risks. The company operates in a highly competitive market, and technological advancements could render its current NGS-based platform obsolete. Regulatory changes in China and reimbursement policy shifts could negatively impact revenue. The company's reliance on the Chinese market exposes it to economic and political risks specific to the region. Furthermore, its current unprofitability and high beta indicate financial and market volatility risks.

Is BNR a good stock to buy?

Whether BNR is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the BNR MoonshotScore?

The MoonshotScore for BNR is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is BNR data updated?

BNR stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to BNR is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for BNR?

Growth catalysts for Burning Rock Biotech Limited (BNR) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Burning Rock Biotech Limited's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are BNR's main competitors?

Burning Rock Biotech Limited (BNR) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether BNR has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about BNR?

Wall Street analyst coverage for BNR includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is BNR's market cap?

Market capitalization (market cap) for BNR is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows BNR's current market cap alongside enterprise value and other valuation metrics.

How has BNR stock performed recently?

BNR's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing BNR's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in BNR?

Key risk categories for BNR include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures BNR's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling BNR?

Insider trading activity for BNR tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is BNR a good stock for beginners?

Burning Rock Biotech Limited (BNR) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is BNR for first-time investors?

Every stock carries risk, including Burning Rock Biotech Limited (BNR). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like BNR.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available reporting period.
  • Forward-looking statements are subject to inherent uncertainties.
Data Sources
profilefundamentalsexistingCopy